There is increasing evidence that in certain lymphoid malignancies, the oncogenic effects of aberrant activation of the NF-κB signaling pathway, either via the tumor microenvironment or through cell-intrinsic genetic mutations, can be mediated by distinct downstream effectors. The gene discussed is NFKB1; the disease is neoplasm.